3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
3
Breast Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Soft Tissue Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Pharyngeal Neoplasms
1
Neurofibromatosis 2
1
Neoplasms, Mesothelial
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphangioleiomyomatosis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Glioma
1
Glioblastoma
1
Erdheim-Chester Disease
1
Endometrial Adenocarcinoma
1
Endocrine Gland Neoplasms
1
Colonic Neoplasms
1
Castleman Disease
1
Carcinoma, Transitional Cell
1
Interventions
Cyclophosphamide
8
asciminib
7
fludarabine phosphate
6
fludarabine
5
Mycophenolic Acid
5
nilotinib
3
Whole-Body Irradiation
3
Thiotepa
3
Tacrolimus
3
Imatinib Mesylate
3
Granulocyte Colony-Stimulating Factor
3
Cyclosporine
3
venetoclax
2
Sirolimus
2
Melphalan
2
Filgrastim
2
Dasatinib
2
Cyclosporins
2
treosulfan
1
thymoglobulin
1
selinexor
1
ruxolitinib
1
ponatinib
1
plerixafor
1
olverembatinib
1
midostaurin
1
merphos
1
gilteritinib
1
bosutinib
1
blinatumomab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
×
temsirolimus
×
30 days
×
Clear all
No trials found.